ANI Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
ANI Pharmaceuticals yıllık ortalama 44.2% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 8.7% annual. Gelirler growing yılda ortalama 31% oranında artmaktadır. ANI Pharmaceuticals'in özkaynak karlılığı 14.5% ve net marjı 7.9%'dir.
Anahtar bilgiler
44.23%
Kazanç büyüme oranı
46.94%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.95% |
| Gelir büyüme oranı | 30.96% |
| Özkaynak getirisi | 14.49% |
| Net Marj | 7.95% |
| Sonraki Kazanç Güncellemesi | 08 May 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
ANIP: 2026 Revenue Guidance And New Launches Will Support Upside Potential
Analysts have kept their $90.00 price target for ANI Pharmaceuticals unchanged, citing relatively steady assumptions for revenue growth, profit margins, and future P/E as the basis for this view. What's in the News Launched Pimozide Tablets 1 mg and 2 mg, a generic version of Orap, with U.S. annual sales for the category of about US$3.1 million based on February 2026 IQVIA data (Key Developments).ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth
Apr 10ANIP: 2026 Revenue Guidance Will Test Confidence In Margin Assumptions
Analysts lifted their price target on ANI Pharmaceuticals by $9, reflecting updated expectations around revenue growth, profit margin, and future P/E assumptions highlighted in recent Street research. Analyst Commentary While the updated target reflects renewed confidence in revenue and margin assumptions, bearish analysts are still flagging several areas where expectations may be running ahead of what the company can reasonably deliver.
ANIP: Higher 2026 Guidance And Margin Outlook Will Support Stronger Earnings Power
Analysts have raised their price target on ANI Pharmaceuticals by $9 to $110.63, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligned with updated expectations for revenue and margin performance, which they factor into their cash flow and earnings models.ANIP: Higher 2026 Guidance Will Test Assumed Margin Expansion
Analysts have lifted their price target on ANI Pharmaceuticals by $9, citing updated assumptions for revenue growth, profit margins, and a revised future P/E multiple that together reshape their view of the stock's long term earnings power. Analyst Commentary While the higher price target reflects updated assumptions, bearish analysts are also flagging several risks that could limit upside if execution or market conditions do not line up with those assumptions.ANIP: Higher 2026 Revenue Guidance Will Support Richer Forward P/E Multiple
Analysts have lifted their price target on ANI Pharmaceuticals by $9, reflecting updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the US$9 price target increase as a sign that updated revenue assumptions support a higher valuation multiple on forward earnings.ANIP: Higher 2026 Revenue Outlook And Refined P/E Framework Will Support Upside
Analysts have raised their price target on ANI Pharmaceuticals by about $1 to $110.50, citing updated views on revenue growth, profit margins, discount rate, and future P/E assumptions reflected in recent research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$110.50 target as better aligned with updated assumptions on revenue and margins, suggesting the stock now reflects their latest fundamental work more closely.ANIP: Future Outlook Will Balance Higher Guidance Expectations And Execution Risks
Analysts have raised their price target on ANI Pharmaceuticals by $9, citing updated expectations for revenue growth, profit margins, and a slightly lower future P/E as key drivers of their revised view. Analyst Commentary While the higher price target signals some confidence around updated revenue and margin expectations, bearish analysts are still flagging areas where the risk and reward profile may feel less attractive for new money.ANIP: Raised Revenue Outlook And Pipeline Update Will Support Further Upside
Narrative Update on ANI Pharmaceuticals Analysts have trimmed their price target on ANI Pharmaceuticals to about $109.25 from roughly $109.88, citing updated assumptions around slightly higher revenue growth expectations, a modestly lower profit margin outlook, and a small adjustment in the forward P/E multiple. What’s in the News ANI Pharmaceuticals raised its full year 2025 net revenue guidance to a range of US$854 million to US$873 million, compared with prior guidance of US$818 million to US$843 million (Key Developments).ANIP: Future Outlook Will Balance Corticotropin Momentum And Concentration Risks
Analysts have raised their price target on ANI Pharmaceuticals to $90 from $77, citing continued momentum from Cortrophin Gel, record Q2 sales of $82M, and a 20% full year guidance increase that supports expectations for sustained growth. Analyst Commentary Bearish analysts acknowledge that the higher $90 price target reflects recent strength, but they emphasize that the rating remains at Hold, signaling caution around near term upside.ANIP: Future Outlook Balances Corticotropin Market Expansion And Competitive Uncertainties
Analysts have lifted their fair value estimate for ANI Pharmaceuticals to $90 from $77 per share as they factor in stronger than expected Cortrophin Gel momentum, higher sales visibility, and an expanding addressable market, despite slightly more conservative growth and margin assumptions. Analyst Commentary Recent Street research reflects a growing divide between optimistic expectations for Cortrophin Gel and a more cautious stance from bearish analysts who question the durability of current momentum and the stock's valuation profile.ANIP: Continued Momentum Will Drive Upside as Market Opportunities Expand
Analysts have raised their price targets for ANI Pharmaceuticals, with increases ranging from $13 to $28 per share. They cite strong Cortrophin Gel sales momentum, expanded market opportunities, and resilient fundamentals as key factors driving the company’s continued growth outlook.ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities
Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.Expanding ACTH Potential And Rare Disease Markets Will Evolve
ANI Pharmaceuticals’ price target was raised to $105.00 as analysts cite robust Cortrophin Gel prescription trends, a significantly expanded addressable market, and outstanding Q2 revenue growth. Analyst Commentary Bullish analysts highlight that Cortrophin Gel prescription data is consistently surpassing forecasts, indicating stronger-than-expected demand.Expanding ACTH Potential And Rare Disease Markets Will Evolve
Despite a meaningful reduction in consensus revenue growth forecasts, ANI Pharmaceuticals’ future P/E multiple has declined, improving perceived value and contributing to an upward revision of the consensus analyst price target from $81.38 to $85.75. What's in the News ANI Pharmaceuticals raised 2025 earnings guidance to $818–$843 million from prior $768–$793 million.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 10
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Jun 21We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation
May 16ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
Mar 28Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Feb 25ANI Pharmaceuticals: More Than Just A Generics Company
Feb 11ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
Dec 18Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Nov 09ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
ANI Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 25 | 883 | 70 | 316 | 52 |
| 30 Sep 25 | 827 | 34 | 304 | 56 |
| 30 Jun 25 | 747 | -13 | 297 | 54 |
| 31 Mar 25 | 674 | -22 | 265 | 45 |
| 31 Dec 24 | 614 | -20 | 232 | 45 |
| 30 Sep 24 | 555 | -9 | 211 | 38 |
| 30 Jun 24 | 539 | 24 | 184 | 39 |
| 31 Mar 24 | 517 | 31 | 173 | 39 |
| 31 Dec 23 | 487 | 15 | 162 | 34 |
| 30 Sep 23 | 449 | 10 | 141 | 30 |
| 30 Jun 23 | 401 | -8 | 129 | 26 |
| 31 Mar 23 | 359 | -28 | 122 | 23 |
| 31 Dec 22 | 316 | -50 | 124 | 22 |
| 30 Sep 22 | 283 | -69 | 112 | 20 |
| 30 Jun 22 | 251 | -65 | 99 | 15 |
| 31 Mar 22 | 226 | -63 | 86 | 14 |
| 31 Dec 21 | 216 | -43 | 84 | 11 |
| 30 Sep 21 | 212 | -22 | 61 | 12 |
| 30 Jun 21 | 213 | -17 | 66 | 16 |
| 31 Mar 21 | 213 | -15 | 62 | 13 |
| 31 Dec 20 | 208 | -23 | 65 | 16 |
| 30 Sep 20 | 199 | -24 | 65 | 17 |
| 30 Jun 20 | 198 | -20 | 57 | 15 |
| 31 Mar 20 | 203 | -1 | 56 | 19 |
| 31 Dec 19 | 207 | 6 | 56 | 20 |
| 30 Sep 19 | 216 | 16 | 55 | 18 |
| 30 Jun 19 | 215 | 17 | 53 | 17 |
| 31 Mar 19 | 208 | 14 | 48 | 18 |
| 31 Dec 18 | 202 | 15 | 44 | 15 |
| 30 Sep 18 | 192 | 0 | 40 | 13 |
| 30 Jun 18 | 189 | 0 | 36 | 11 |
| 31 Mar 18 | 187 | 0 | 33 | 10 |
| 31 Dec 17 | 177 | -1 | 32 | 9 |
| 30 Sep 17 | 168 | 7 | 30 | 7 |
| 30 Jun 17 | 158 | 5 | 29 | 5 |
| 31 Mar 17 | 145 | 4 | 28 | 4 |
| 31 Dec 16 | 129 | 4 | 27 | 3 |
| 30 Sep 16 | 108 | 8 | 25 | 3 |
| 30 Jun 16 | 90 | 10 | 23 | 3 |
| 31 Mar 16 | 78 | 12 | 22 | 3 |
| 31 Dec 15 | 76 | 15 | 21 | 3 |
| 30 Sep 15 | 79 | 33 | 20 | 3 |
| 30 Jun 15 | 77 | 35 | 19 | 3 |
Kaliteli Kazançlar: ANIP büyük bir tek seferlik kazanç ile $30.6M, 31st December, 2025 tarihine ait son 12 aylık mali sonuçları etkiliyor.
Büyüyen Kar Marjı: ANIP geçmişte karlı hale geldi.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ANIP son 5 yılda karlı hale geldi ve kazançlarını yıllık 44.2% oranında artırdı.
Büyüme Hızlandırma: ANIP son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.
Kazançlar vs. Sektör: ANIP son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( -3.3% ) karşılaştırılmasını zorlaştırıyor.
Özkaynak Getirisi
Yüksek ROE: ANIP 'nin Özsermaye Getirisi ( 14.5% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/04 21:40 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ANI Pharmaceuticals, Inc. 16 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Glen Santangelo | Barclays |
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |